Author/Authors :
Kim، نويسنده , , Yun-Hee and Sung، نويسنده , , Ho Jin and Kim، نويسنده , , Sukyoung and Kim، نويسنده , , Eun-Ok and Lee، نويسنده , , Ji Won and Moon، نويسنده , , Ju-Young and Choi، نويسنده , , Kyungho and Jung، نويسنده , , Ji-Eun and Lee، نويسنده , , Yangsoon and Koh، نويسنده , , Sang Seok and Rhee، نويسنده , , Sue Goo and Heo، نويسنده , , Kyun and Kim، نويسنده , , In-Hoo، نويسنده ,
Abstract :
Previously, we reported that a novel secretory protein, pancreatic adenocarcinoma up-regulated factor (PAUF), which is highly expressed in pancreatic cancer and mediates the growth and metastasis of pancreatic cancer cells. In this study, we generated and characterized a 2′-fluoropyrimidine modified RNA aptamer (P12FR2) directed against human PAUF. P12FR2 binds specifically to human PAUF with an estimated apparent KD of 77 nM. P12FR2 aptamer inhibits PAUF-induced migration of PANC-1, human pancreatic cancer cells, in a wound healing assay. Moreover, intraperitoneal injection of P12FR2 decreased tumor growth by about 60% in an in vivo xenograft model with CFPAC-1 pancreatic cancer cells, without causing a loss of weight in the treated mice. Taken together, we propose here that PAUF-specific RNA aptamer, P12FR2, has the potential to be effective in the therapy of human pancreatic cancer.
Keywords :
Aptamer , PAUF , pancreatic cancer , SELEX , Anticancer drug
